Dr. Reddy's Explains Canadian Semaglutide Approval Status

Dr. Reddy's Laboratories provided an update on its Semaglutide Injection in Canada on April 24, 2026. The company confirmed it has received Drug Identification Numbers (DINs) for the product from Health Canada on April 22, 2026.

However, Dr. Reddy's stated that the final market launch approval, known as a 'Notice of Compliance' (NOC), is still pending from Health Canada.

Key Regulatory Step Reached

Receiving DINs signifies that Health Canada has reviewed and accepted the product's basic identification details. This is a step forward in the regulatory pathway.

Launch Date Remains Unclear

The absence of the final 'Notice of Compliance' means the Semaglutide Injection cannot yet be marketed or sold in Canada. This delays the drug's potential contribution to the company's revenue.

Market Significance of Semaglutide

Semaglutide is a key medication used for diabetes and obesity treatment. Its market entry is highly anticipated, with Dr. Reddy's aiming to capture a share of this growing global market.

Health Canada's drug approval process is thorough, involving multiple stages to ensure product safety and efficacy before market authorization.

Clarity for Investors

The company's clarification provides investors with a clearer understanding of the approval process. While progress is being made with the DINs, a specific launch date for Canada is not yet established.

Dr. Reddy's remains committed to launching Semaglutide in Canada and continues to engage with Health Canada.

Regulatory Hurdles

The primary risk is the uncertainty surrounding the final timeline for receiving the 'Notice of Compliance'. This delay could affect Dr. Reddy's market entry timing.

Industry Competitors

Dr. Reddy's operates in a competitive landscape. Other pharmaceutical companies, including Sun Pharma, Cipla, and Lupin, are also active in global markets and navigate similar regulatory processes for new drug launches.